Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (84)

« Back to Publications

B and T cell responses to pre-erythrocytic R21/Matrix-M and blood-stage RH5.1/Matrix-M malaria vaccines in endemic settings.

Bundi CK. et al, (2026), Front Immunol, 17

Structural basis for synergistic antibody protection against the essential malaria invasion complex protein RIPR

Williams BG. et al, (2025)

Structural basis for synergistic antibody protection against the essential malaria invasion complex protein RIPR

Williams BG. et al, (2025)

B and T cell responses to pre-erythrocytic R21/Matrix-M and blood-stage RH5.1/Matrix-M malaria vaccines in endemic settings

Bundi CK. et al, (2025)

Addition of blood stage monoclonal antibody improves protection afforded by anti-sporozoite antibody alone in a humanized mouse model of Plasmodium falciparum malaria

Kirtley P. et al, (2025)

Diagnosis of Plasmodium falciparum malaria at very low parasitaemias using a commercially available LAMP assay and RDT.

Payne RO. et al, (2025), Trans R Soc Trop Med Hyg, 119, 1149 - 1156

Development of clinical immunity to Plasmodium vivax following repeat controlled human malaria infection.

Hou MM. et al, (2025), Nat Commun, 16

Plasmodium falciparum infection induces T cell tolerance that is associated with decreased disease severity upon re-infection.

Muñoz Sandoval D. et al, (2025), J Exp Med, 222

Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in children.

Natama HM. et al, (2025), Lancet Infect Dis, 25, 495 - 506

An experimental model of clinical immunity for human malaria

Hou MM. et al, (2025)

Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled phase 2b trial in children

Natama HM. et al, (2024)

Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial.

Silk SE. et al, (2024), Lancet Infect Dis, 24, 1105 - 1117

Natural malaria infection elicits rare but potent neutralizing antibodies to the blood-stage antigen RH5.

Wang LT. et al, (2024), Cell, 187, 4981 - 4995.e14

Analysis of the diverse antigenic landscape of the malaria protein RH5 identifies a potent vaccine-induced human public antibody clonotype.

Barrett JR. et al, (2024), Cell, 187, 4964 - 4980.e21

Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodies.

King LDW. et al, (2024), Cell Rep Med, 5

Load More

1
2
3
4
5
6